These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31098918)

  • 21. A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports.
    Tatonetti NP; Fernald GH; Altman RB
    J Am Med Inform Assoc; 2012; 19(1):79-85. PubMed ID: 21676938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse Event Reports Associated with Vaginal Mesh: An Interrupted Time Series Analysis.
    Leiter V; White SK; Walters A
    Womens Health Issues; 2017; 27(3):279-285. PubMed ID: 28233636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of litigation in defining drug risks.
    Kesselheim AS; Avorn J
    JAMA; 2007 Jan; 297(3):308-11. PubMed ID: 17227983
    [No Abstract]   [Full Text] [Related]  

  • 25. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
    Raisch DW; Rafi JA; Chen C; Bennett CL
    Expert Opin Drug Saf; 2016 Aug; 15(8):1003-11. PubMed ID: 27268272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System.
    Bluestein SB; Yu R; Stone C; Phillips EJ
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3208-3211.e1. PubMed ID: 34033979
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA Adverse Event Reporting System: Recruiting Doctors to Make Surveillance a Little Less Passive.
    Mann JM
    Food Drug Law J; 2015; 70(3):371-94, i. PubMed ID: 26630821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA's role in drug product recalls.
    Crawford SY
    Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
    [No Abstract]   [Full Text] [Related]  

  • 32. Changing the culture of medicine: the FDA's MEDWatch program.
    Kessler DA
    Acad Med; 1993 Oct; 68(10):776-7. PubMed ID: 8397603
    [No Abstract]   [Full Text] [Related]  

  • 33. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
    Moore TJ; Furberg CD; Mattison DR; Cohen MR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MedWatch: FDA's Medical Products Reporting Program.
    Goldman SA; Kennedy DL
    Postgrad Med; 1998 Mar; 103(3):13-6. PubMed ID: 9519028
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA's MedWatch Program Monitors Drug Safety, But It Depends on Nurses to Report Adverse Events.
    Miller D
    ONS Connect; 2015 Sep; 30(3):49. PubMed ID: 26449124
    [No Abstract]   [Full Text] [Related]  

  • 36. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

  • 37. IOM panel mulls over adverse-event reporting.
    Young D
    Am J Health Syst Pharm; 2005 Dec; 62(24):2590-1. PubMed ID: 16333055
    [No Abstract]   [Full Text] [Related]  

  • 38. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
    Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.